FDA declines to approve Durect's pain drug
(Reuters) - U.S. Food and Drug Administration declined to approve Durect Corp's post-operative pain treatment, saying the application lacked enough data to prove the drug was safe.
Durect's shares fell about 30 percent after the bell.
The FDA indicated that more clinical safety studies would have to be conducted on the drug, Posidur, Durect said.
The specialty pharmaceutical company said it was evaluating the issues described in the "complete response letter", the type of letter issued by the FDA to convey that it cannot approve a drug application in its current form.
Durect's shares closed at $1.95 Wednesday on the Nasdaq.
(Reporting by Shailesh Kuber; Editing by Don Sebastian)
- Protesters stay out on Hong Kong streets, defying Beijing |
- Hong Kong protesters stockpile supplies, prepare for long haul |
- China OKs iPhone 6 sale after Apple addresses security concerns
- Stocks head for worst quarter since euro crisis, dollar reigns
- U.S.-led air strikes pose problem for Assad's moderate foes